Drugs / PR610
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01631279 | Aug 2012 → Mar 2015 | cancer of unknown primary site | Proacta, Incorporated | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PR610 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01631279 ↗ |
| Route | Intravenous | “PR610 is administered intravenously weekly.” NCT01631279 ↗ |